NDUFA4L2 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2) is a hypoxia-inducible factor 1α (HIF-1α) target gene that modulates mitochondrial respiratory chain activity by reducing oxygen consumption and reactive oxygen species (ROS) production. It is upregulated in multiple cancers, including glioblastoma (GBM), renal cell carcinoma, and osteosarcoma, where it promotes tumor survival and chemoresistance.
Key Features of NDUFA4L2 Protein
Molecular Weight: ~10–15 kDa (species-dependent)
Localization: Mitochondria
Function: Suppresses Complex I activity, enhances hypoxia adaptation
Regulation: Primarily HIF-1α-dependent (except in GBM)
NDUFA4L2 Antibody Characteristics
Commercially available NDUFA4L2 antibodies are validated for applications including Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and ELISA. Two prominent examples include:
Table 1: Comparison of Leading NDUFA4L2 Antibodies
Parameter
Polyclonal (OASG04867)
Monoclonal (66050-1-Ig)
Host Species
Rabbit
Mouse
Clonality
Polyclonal
Monoclonal (Clone 1G1H10)
Reactivity
Human, Mouse
Human
Applications
WB, ELISA
WB, IHC, IF/ICC, ELISA
Immunogen
C-terminal peptide (30–110 aa)
Full-length protein
Molecular Weight
15 kDa (human)
10 kDa (human)
Vendor
Aviva Systems Biology
Proteintech
Citations
Cancer Mechanistic Studies
NDUFA4L2 antibodies have been instrumental in uncovering its oncogenic roles:
NDUFA4L2 promotes metastasis by regulating ROS and epithelial-mesenchymal transition (EMT) markers (e.g., E-cadherin, Vimentin).
Table 2: Key Research Findings Using NDUFA4L2 Antibodies
Cancer Type
Major Findings
Method
Citation
Glioblastoma
NDUFA4L2 overexpression correlates with poor survival; apatinib targets NDUFA4L2
WB, IHC
Renal Cell Carcinoma
NDUFA4L2 sustains chemoresistance and mitochondrial dysfunction
WB, IF
Osteosarcoma
NDUFA4L2 knockdown inhibits tumor growth and metastasis in vivo
WB, IHC
Therapeutic Implications
NDUFA4L2 antibodies enable the development of targeted therapies:
Apatinib: Reduces NDUFA4L2 expression in GBM, synergizing with mitophagy blockers to enhance apoptosis.
HIF-1α-Independent Pathways: In GBM, NDUFA4L2 is not regulated by HIF-1α, necessitating alternative targeting strategies.
Validation and Protocols
Western Blot: Optimized dilution ranges from 1:500 to 1:2000, with expected bands at ~10–15 kDa.
Immunohistochemistry: Antigen retrieval recommended using TE buffer (pH 9.0) or citrate buffer (pH 6.0).
Immunofluorescence: Used to confirm mitochondrial localization in hypoxic cancer cells.
Product Specs
Buffer
PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. Store at -20°C. Avoid repeated freeze-thaw cycles.
Lead Time
We typically dispatch orders within 1-3 business days of receipt. Delivery times may vary depending on the purchasing method and location. Please contact your local distributor for specific delivery time estimates.
